# Ransi Nayakarathna

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/ransi-nayakarathna/

## Facts

| Field | Value |
| --- | --- |
| Citations | 28 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 2 |
| i10-index | 1 |
| OpenAlex ID | https://openalex.org/A5045650346 |
| Works | 3 |

## Researcher papers

- [Early access for innovative oncology medicines: a different story in each nation](https://scholariq.org/papers/early-access-for-innovative-oncology-medicines-a-different-story-in-each-nation/)
- [Virtual Care Use in Primary Care or Specialty Care Settings](https://scholariq.org/papers/virtual-care-use-in-primary-care-or-specialty-care-settings/)
- [Low-Dose Ipilimumab in Combination With Nivolumab or Pembrolizumab for the Treatment of Advanced Melanoma](https://scholariq.org/papers/low-dose-ipilimumab-in-combination-with-nivolumab-or-pembrolizumab-for-the/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Health Systems, Economic Evaluations, Quality of Life](https://scholariq.org/topics/health-systems-economic-evaluations-quality-of-life/)
- [Telemedicine and Telehealth Implementation](https://scholariq.org/topics/telemedicine-and-telehealth-implementation/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.